Prognostic factors in ALS: a comparison between Germany and China.
Amyotrophic lateral sclerosis
China
Germany
Motor neuron disease
Prognostic factors
Survival
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
21
02
2019
accepted:
19
03
2019
revised:
15
03
2019
pubmed:
30
3
2019
medline:
18
12
2019
entrez:
30
3
2019
Statut:
ppublish
Résumé
Several independent prognostic factors, such as age of onset, type of onset, body mass index (BMI), and progression rate have been identified for amyotrophic lateral sclerosis (ALS) in Caucasians. The aim of this study was to identify such factors in Chinese patients and to compare their impact with German patients. Comparison of prognostic factors was based on two hospital-based registries. The registry of the German Network for Motor Neuron Diseases contains 3100 patients with ALS. The Chinese registry comprises 2101 patients who were collected between 2003 and 2015 in the metropolitan area of Beijing. Disease progression was slower in China [median loss of 0.50 points (IQR 0.26-0.87 points) versus 0.55 points (IQR 0.28-1.00 points) of ALS functional rating scale revised (ALS-FRS-R) score per month; p < 0.0001]. Survival of patients with ALS was similar in Germany and China (p > 0.05). We found that younger age of onset (p < 0.0001), spinal onset (p < 0.0001), high BMI (p < 0.0001) and low progression rate (p < 0.0001) were positive prognostic factors in China as well as in Germany. Prognostic factors, which are known to modify the course of disease in Caucasians, apply to Chinese patients as well. The results indicate that despite the apparent differences regarding genotype and clinical phenotype, findings from interventional studies in Caucasians aiming at disease-modifying prognostic factors (such as body weight) may be transferred to Chinese patients.
Identifiants
pubmed: 30923935
doi: 10.1007/s00415-019-09290-4
pii: 10.1007/s00415-019-09290-4
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1516-1525Subventions
Organisme : Bundesministerium für Bildung und Forschung
ID : 01GM1103A
Organisme : National Natural Science Foundation of China
ID : 81701248
Organisme : National Natural Science Foundation of China
ID : 81873784
Références
Desport JC, Preux PM, Truong TC, Vallat JM, Sautereau D, Couratier P (1999) Nutritional status is a prognostic factor for survival in ALS patients. Neurology 53(5):1059–1063
doi: 10.1212/WNL.53.5.1059
pubmed: 10496266
Wills AM, Hubbard J, Macklin EA, Glass J, Tandan R, Simpson EP et al (2014) Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. https://doi.org/10.1016/s0140-6736(14)60222-1
doi: 10.1016/s0140-6736(14)60222-1
pubmed: 24582471
pmcid: 4176708
Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar JL, Bonnefont-Rousselot D, Bittar R et al (2008) Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 70(13):1004–1009. https://doi.org/10.1212/01.wnl.0000285080.70324.27
doi: 10.1212/01.wnl.0000285080.70324.27
pubmed: 18199832
Jawaid A, Salamone AR, Strutt AM, Murthy SB, Wheaton M, McDowell EJ et al (2010) ALS disease onset may occur later in patients with pre-morbid diabetes mellitus. Eur J Neurol 17(5):733–739. https://doi.org/10.1111/j.1468-1331.2009.02923.x
doi: 10.1111/j.1468-1331.2009.02923.x
pubmed: 20074230
Chio A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA et al (2013) Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 41(2):118–130
doi: 10.1159/000351153
pubmed: 23860588
pmcid: 4049265
Al-Chalabi A, Hardiman O (2013) The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol 9(11):617–628
doi: 10.1038/nrneurol.2013.203
pubmed: 24126629
Rosenbohm A, Peter RS, Erhardt S, Lule D, Rothenbacher D, Ludolph AC et al (2017) Epidemiology of amyotrophic lateral sclerosis in Southern Germany. J Neurol 264(4):749–757
doi: 10.1007/s00415-017-8413-3
pubmed: 28220290
Chen L, Zhang B, Chen R, Tang L, Liu R, Yang Y et al (2015) Natural history and clinical features of sporadic amyotrophic lateral sclerosis in China. J Neurol Neurosurg Psychiatry 86(10):1075–1081
doi: 10.1136/jnnp-2015-310471
pubmed: 26124198
Nalini A, Thennarasu K, Gourie-Devi M, Shenoy S, Kulshreshtha D (2008) Clinical characteristics and survival pattern of 1,153 patients with amyotrophic lateral sclerosis: experience over 30 years from India. J Neurol Sci 272(1–2):60–70
doi: 10.1016/j.jns.2008.04.034
pubmed: 18550082
Atsuta N, Watanabe H, Ito M, Tanaka F, Tamakoshi A, Nakano I et al (2009) Age at onset influences on wide-ranged clinical features of sporadic amyotrophic lateral sclerosis. J Neurol Sci 276(1–2):163–169
doi: 10.1016/j.jns.2008.09.024
pubmed: 18962725
Rosenbohm A, Liu M, Nagel G, Peter RS, Cui B, Li X et al (2018) Phenotypic differences of amyotrophic lateral sclerosis (ALS) in China and Germany. J Neurol 265(4):774–782
doi: 10.1007/s00415-018-8735-9
pubmed: 29392461
Brooks BR, Miller RG, Swash M, Munsat TL (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrop Later Scler Other Motor Neuron Disord 1(5):293–299
doi: 10.1080/146608200300079536
Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B et al (1999) The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 169(1–2):13–21
doi: 10.1016/S0022-510X(99)00210-5
EdavaroneStudyGroup (2017) Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 15(17):30111–30115
Ludolph AC, Schuster J, Dorst J, Dupuis L, Dreyhaupt J, Weishaupt JH et al (2018) Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. Lancet Neurol 18(18):30175–30176
Liu X, He J, Gao FB, Gitler AD, Fan D (2018) The epidemiology and genetics of Amyotrophic lateral sclerosis in China. Brain Res 15:121–126
doi: 10.1016/j.brainres.2018.02.035
Wei Q, Chen X, Zheng Z, Huang R, Guo X, Cao B et al (2015) Clinical features of amyotrophic lateral sclerosis in south-west China. Amyotrop Later Scler Frontotemp Degen 16(7–8):512–519
doi: 10.3109/21678421.2015.1069849
Cui F, Liu M, Chen Y, Huang X, Cui L, Fan D et al (2014) Epidemiological characteristics of motor neuron disease in Chinese patients. Acta Neurol Scand 130(2):111–117
doi: 10.1111/ane.12240
pubmed: 24689740
Zhou S, Qian S, Li X, Zheng L, Chang W, Wang L (2018) Using the capture-recapture method to estimate the incidence of amyotrophic lateral sclerosis in Beijing, China. Neuroepidemiology 50(1–2):29–34
doi: 10.1159/000486175
pubmed: 29324454
Wais V, Rosenbohm A, Petri S, Kollewe K, Hermann A, Storch A et al (2017) The concept and diagnostic criteria of primary lateral sclerosis. Acta Neurol Scand 136(3):204–211
doi: 10.1111/ane.12713
pubmed: 27858953
Pradat PF, Bruneteau G, Gordon PH, Dupuis L, Bonnefont-Rousselot D, Simon D et al. Impaired glucose tolerance in patients with amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis: official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases. 2010;11(1–2):166–71. https://doi.org/10.3109/17482960902822960
Desport JC, Torny F, Lacoste M, Preux PM, Couratier P (2005) Hypermetabolism in ALS: correlations with clinical and paraclinical parameters. Neurodegener Dis 2(3–4):202–207
doi: 10.1159/000089626
pubmed: 16909026
Bensimon G, Lacomblez L, Meininger V, ALS/Riluzole Study Group (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 330(9):585–591. https://doi.org/10.1056/nejm199403033300901
doi: 10.1056/NEJM199403033300901
pubmed: 8302340
Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 347(9013):1425–1431
doi: 10.1016/S0140-6736(96)91680-3
pubmed: 8676624
Zou ZY, Zhou ZR, Che CH, Liu CY, He RL, Huang HP (2017) Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 88(7):540–549
doi: 10.1136/jnnp-2016-315018
pubmed: 28057713
Mariosa D, Kamel F, Bellocco R, Ye W, Fang F (2015) Association between diabetes and amyotrophic lateral sclerosis in Sweden. Eur J Neurol 22(11):1436–1442
doi: 10.1111/ene.12632
pubmed: 25600257
pmcid: 4506907